Defining a Clinically Meaningful Within-Person Change Threshold for the Psychomotor Vigilance Test in Narcolepsy Type 1.

In 30 seconds

This analysis of two randomized, placebo-controlled phase III trials established a meaningful within-person change threshold for Psychomotor Vigilance Test (PVT) lapses and assessed attention changes in people with narcolepsy type 1. Anchor- and distribution-based methods, supported by receiver operating characteristic analysis, identified a reduction of ≥ - 2 PVT lapses as meaningful. At day 84, this threshold was met by 66.9% versus 25.7% of participants receiving oveporexton versus placebo in The First Light, and 57.6% versus 17.6% in The Radiant Light (both P ≤ 0.0001).

Key findings

• A reduction of ≥ - 2 PVT lapses was supported as a meaningful improvement in attention.
• In The First Light, 66.9% of oveporexton-treated participants versus 25.7% receiving placebo met the threshold at day 84.
• In The Radiant Light, 57.6% of oveporexton-treated participants versus 17.6% receiving placebo met the threshold at day 84; both trial comparisons had P ≤ 0.0001.

Why it matters

The analysis links a change in an objective attention measure to patient-reported improvement, helping clinicians interpret whether PVT changes may be meaningful rather than merely numerical. The trial results suggest that meaningful attention improvement was more common with oveporexton than placebo in these NT1 study populations.

What to keep in mind

The threshold was derived and evaluated using data from two specific phase III trials; its applicability beyond these trial populations is not established in the abstract.